A 83-01

• UNSPSC Description:

  A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively[1].

• Target Antigen:

  Organoid; TGF-β Receptor

• Type:

  Reference compound

• Related Pathways:

  Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/A-83-01.html

• Purity:

  99.41

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5

• Molecular Weight:

  421.52

• References & Citations:

  [1]Tojo M, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005 Nov;96(11):791-800.|[2]Yamamura S, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012 Jan 1;130(1):20-8.|[3]Taniguchi Y, et al. Enhanced antitumor efficacy of folate-linked liposomal Adriamycin with TGF-β type I receptor inhibitor. Cancer Sci. 2010 Oct;101(10):2207-13.Acta Pharmacol Sin. 2024 Jul 25.|Adv Sci (Weinh). 2022 Sep;9(26):e2202505.|Adv Sci (Weinh). 2024 Sep 24:e2402299.|Am J Physiol Cell Physiol. 2023 May 1.|bioRxiv. 2024 August 11.|bioRxiv. 2024 Feb 27.|bioRxiv. 2024 July 22.|bioRxiv. 2024 November 18.|Cell Death Dis. 2024 Aug 3;15(8):559.|Cell Prolif. 2022 Aug 3;e13320.|Cell Prolif. 2024 Jan 12:e13599.|Cell Rep. 2022 Jul 12;40(2):111053.|Cell Rep. 2023 May 23;42(6):112546.|Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10.|Cell. 2024 Nov 14;187(23):6566-6583.e22.|Cells. 2024 Aug 31.|FASEB J. 2020 Aug;34(8):11185-11199.|FASEB J. 2023 Dec;37(12):e23279.|FASEB J. 2023 Jul;37(7):e22983.|Front Med. 2021 Sep 23;8:746298.|Genome Med. 2024 Apr 24;16(1):60|Gynecol Oncol. 2019 Jun;153(3):639-650.|Int J Cancer. 2024 Jan 28.|Int J Mol Sci. 2023 Dec 29, 25(1), 477.|Int J Radiat Oncol Biol Phys. 2023 Oct 9:S0360-3016(23)07970-1.|J Pharm Anal. 2023 Sep 22.|J Transl Med. 2021 Dec 7;19(1):497.|Methods Mol Biol. 2021 Jun 15.|Methods Mol Biol. 2022 Dec 15.|Methods Mol Biol. 2023 Jun 24.|Mol Cancer. 2024 Jan 10;23(1):12.|Mol Oncol. 2023 Oct 23.|Nano Res. 03 August 2022.|Nat Cell Biol. 2022 Jun;24(6):858-871.|Nat Commun. 2022 Sep 6;13(1):5237.|Nat Genet. 2024 Feb;56(2):294-305.|Nat Protoc. 2023 Feb 15.|Patent. US20220389379A1.|Patent. US20240344020A1.|Reprod Toxicol. 2023 Dec 12:123:108522.|Research Square Preprint. 2021 Jan.|Sci Adv. 2021 Apr 14;7(16):eabb2213.|Sci Adv. 2023 Dec 22;9(51):eadi5683.|SSRN. 2024 May 23.|SSRN. 2024 May 30.|Stem Cell Res Ther. 2024 Dec 18;15(1):478.|Theranostics. 2021 Mar 14;11(11):5539-5552.|Theranostics. 2024 Jan 1;14(3):1049-1064.|J Biol Chem. 2022 Aug 12;102374.|Science. 2020 Dec 4;370(6521):eaay2002.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  909910-43-6